Treatment of refractory thrombotic thrombocytopenic purpura with N-Acetylcysteine: A case report

Transfusion

Volumn 54, Issue 5, 2014, Pages 1221-1224

  Li, Gloria W ^a,b   Rambally, Siayareh ^a,b   Kamboj, Jasmine ^a,b   Reilly, Sean ^c   Moake, Joel L ^a   Udden, Mark M ^a,b   Mims, Martha P ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BEN TAUB GENERAL HOSPITAL   (United States)

^c HARRIS COUNTY HOSPITAL DISTRICT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DEXAMETHASONE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SMEAR; CASE REPORT; COMA; CONFUSION; CORTICOSTEROID THERAPY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; GENERAL CONDITION DETERIORATION; HUMAN; JAUNDICE; LABORATORY TEST; LOADING DRUG DOSE; MALAISE; PARESTHESIA; PLASMA TRANSFUSION; PLASMAPHERESIS; TACHYCARDIA; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; URINE COLOR; VISUAL IMPAIRMENT;

ACETYLCYSTEINE; ADAM PROTEINS; ADULT; FEMALE; HUMANS; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84900426373     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12440     Document Type: Article

References (18)

1. George JN,. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935. (Pubitemid 43872694)
2. George JN, Al-Nouri ZL,. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program 2012; 2012: 604-609.
3. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-1584. (Pubitemid 28536132)
4. Tsai HM, Lian EC,. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594. (Pubitemid 28536133)
5. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-397.
6. George JN,. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-4069.
7. Chen J, Reheman A, Gushiken FC, et al. N-Acetylcysteine reduces the size and activity of von-Willebrand factor in human plasma and mice. J Clin Invest 2011; 121: 593-603.
8. Kelly GS,. Clinical applications of N-Acetylcysteine. Altern Med Rev 1998; 3: 114-127. (Pubitemid 128709607)
9. Balduini CL, Gugliotta L, Luppi M, et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study. Ann Hematol 2010; 89: 591-596.
10. Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory TTP: the experience of the Oklahoma registry, 1989-2006. Transfusion 2008; 48: 349-357.
11. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
12. Tun NM, Villani GM,. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis. J Thromb Thrombolysis 2012; 34: 347-359.
13. Turner N, Nolasco L, Moake J,. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. Semin Thromb Hemost 2012; 38: 38-46.
14. Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 762-774.
15. Tsai E, Chapin J, Laurence JC, et al. Use of eulizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: Additional data and clinical follow-up. Br J Haematol 2013; 162: 558-559.
16. Jepsen S, Hansen AB,. The influence of N-Acetylcysteine on the measurement of prothrombin time and activated partial thromboplastin time in healthy subjects. Scand J Clin Lab Invest 1994; 54: 543-547.
17. Wijeysundera DN, Karkouti K, Rao V, et al. N-Acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery. Crit Care Med 2009; 37: 1929-1934.
18. ClinicalTrials.gov. N-Acetylcysteine in TTP. NCT01808521. 2013. [cited 2013 Sep 17]. Available from: http://clinicaltrials.gov/ct2/show/NCT01808521? term=n-Acetyl+cysteine+TTP&rank=1